Atara Biotherapeutics, Inc.
ATRA
$9.81
$1.0311.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.13% | -91.41% | -38.63% | 258.77% | 670.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.13% | -91.41% | -38.63% | 258.77% | 670.30% |
| Cost of Revenue | -96.45% | -94.13% | -88.03% | -10.37% | -53.22% |
| Gross Profit | -92.41% | 103.78% | -29.12% | 450.22% | 124.95% |
| SG&A Expenses | -64.32% | -61.86% | -33.40% | 2.61% | -9.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -84.40% | -88.70% | -72.36% | -8.02% | -21.86% |
| Operating Income | 55.61% | 83.70% | 126.41% | 283.48% | 77.10% |
| Income Before Tax | 73.21% | 80.50% | 112.55% | 219.80% | 78.97% |
| Income Tax Expenses | 100.00% | 264.71% | -- | -- | -272.73% |
| Earnings from Continuing Operations | 73.17% | 80.36% | 112.53% | 219.71% | 79.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.17% | 80.36% | 112.53% | 219.71% | 79.00% |
| EBIT | 55.61% | 83.70% | 126.41% | 283.48% | 77.10% |
| EBITDA | 60.66% | 84.08% | 132.98% | 300.80% | 78.68% |
| EPS Basic | 78.90% | 89.19% | 106.31% | 162.53% | 91.52% |
| Normalized Basic EPS | 61.28% | 89.34% | 110.54% | 192.61% | 90.45% |
| EPS Diluted | 78.91% | 89.10% | 106.13% | 161.95% | 91.51% |
| Normalized Diluted EPS | 61.28% | 89.34% | 110.45% | 191.86% | 90.45% |
| Average Basic Shares Outstanding | 27.18% | 81.68% | 98.55% | 91.43% | 147.61% |
| Average Diluted Shares Outstanding | 27.18% | 81.68% | 100.39% | 92.98% | 147.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |